In patients with acute myeloid leukemia (AML), the healthy bone marrow is overtaken by blasts that, under normal cell development, would have become (non-lymphoid) white blood cells, red blood cells or platelets.
We also have one of the few hematologic malignancy (leukemia, lymphoma and myeloma) research programs in the country that is approved and funded by the National Cancer Institute. In fact, Penn pioneered the clinical trial using autologous transplant for acute myeloid leukemia (AML). This innovation led to national trials which resulted in the use of autologous transplant as the standard of care for AML.
Learn more about our Leukemia Program